[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fiOLoGUppxOlGoScFkBNknoMMjO1dzb2vLIrx7rbXzIg":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":64,"rows":71},"Göteborg University",[4],267,false,61,17,70817,11,218,[14,17,20,23,26,28,31,33],{"name":15,"count":16},"Obesity",16,{"name":18,"count":19},"Stroke",8,{"name":21,"count":22},"Hypertension",7,{"name":24,"count":25},"Physical Activity",6,{"name":27,"count":25},"Fibromyalgia",{"name":29,"count":30},"Chronic Pain",5,{"name":32,"count":30},"Inflammation",{"name":34,"count":30},"Peri-Implantitis",[36,41,46,49,54,59],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT05637853","Telemonitored Fast Track Medical Sequencing for Heart Failure With Reduced Ejection Fraction","2024-08-26","GDMT",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT05296356","OSU6162 in Bipolar Depression (OBID)","2026-05-31","OSU6162",{"nctId":47,"briefTitle":48,"date":44,"intervention":45},"NCT05641623","OSU6162 as add-on in SSRI\u002FSNRI-resistant Depression",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT04589325","Ixekizumab Diabetes Intervention Trial (I-DIT)","2027-02","Ixekizumab",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT05797558","Unilateral Primary Aldosteronism, Mineralocorticoid Antagonists Versus Surgical Treatment","2028-05-28","Medical treatment",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT03756961","Effects of an Opioid Free\u002FSparing Care Pathway for Patients Undergoing Obesity Surgery","2028-05-31","Dexmedetomidine",[65,66,67,68,69,70],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[72,97,134,156,184,202,220,238,256,274,292,313,363,388,414,440,458,483,509,527,545,570,595,619,644,662,680,708,726,744,780,807,825,843,861,887,909,933,958,982,1000,1025,1052,1070,1096,1125,1150,1174,1192,1218,1244,1269,1294,1312,1330,1353,1375,1399,1424,1442,1468,1492,1517,1542,1565,1589,1613],{"intervention":40,"totalTrials":73,"cells":74},1,{"EARLY_PHASE1":75,"PHASE1":78,"PHASE2":80,"PHASE3":82,"PHASE4":84,"NA":95},{"trials":76,"activeCount":77},[],0,{"trials":79,"activeCount":77},[],{"trials":81,"activeCount":77},[],{"trials":83,"activeCount":77},[],{"trials":85,"activeCount":73,"soonestReadout":39},[86],{"nctId":37,"briefTitle":38,"status":87,"phases":88,"primaryCompletion":39,"completion":89,"start":90,"enrollment":91,"conditions":92,"interventions":94},"ACTIVE_NOT_RECRUITING",[69],"2026-08-26","2022-10-22",60,[93],"Heart Failure With Reduced Ejection Fraction",[40],{"trials":96,"activeCount":77},[],{"intervention":45,"totalTrials":98,"cells":99},2,{"EARLY_PHASE1":100,"PHASE1":102,"PHASE2":104,"PHASE3":128,"PHASE4":130,"NA":132},{"trials":101,"activeCount":77},[],{"trials":103,"activeCount":77},[],{"trials":105,"activeCount":98,"soonestReadout":44},[106,115],{"nctId":42,"briefTitle":43,"status":107,"phases":108,"primaryCompletion":44,"completion":109,"start":110,"enrollment":111,"conditions":112,"interventions":114},"RECRUITING",[67],"2027-05-31","2021-10-25",22,[113],"Bipolar Depression",[45],{"nctId":47,"briefTitle":48,"status":107,"phases":116,"primaryCompletion":44,"completion":117,"start":118,"enrollment":119,"conditions":120,"interventions":127},[67],"2026-08-31","2022-04-21",180,[121,122,123,124,125,126],"Depression","Depressive Disorder, Treatment-Resistant","Depressive Disorder","Depressive Episode","Recurrent Depressive Disorder","Recurrent Depression",[45],{"trials":129,"activeCount":77},[],{"trials":131,"activeCount":77},[],{"trials":133,"activeCount":77},[],{"intervention":53,"totalTrials":73,"cells":135},{"EARLY_PHASE1":136,"PHASE1":138,"PHASE2":140,"PHASE3":150,"PHASE4":152,"NA":154},{"trials":137,"activeCount":77},[],{"trials":139,"activeCount":77},[],{"trials":141,"activeCount":73,"soonestReadout":52},[142],{"nctId":50,"briefTitle":51,"status":87,"phases":143,"primaryCompletion":52,"completion":144,"start":145,"enrollment":146,"conditions":147,"interventions":149},[67],"2027-12","2022-11-09",127,[148],"Type1 Diabetes Mellitus",[53],{"trials":151,"activeCount":77},[],{"trials":153,"activeCount":77},[],{"trials":155,"activeCount":77},[],{"intervention":63,"totalTrials":73,"cells":157},{"EARLY_PHASE1":158,"PHASE1":160,"PHASE2":162,"PHASE3":164,"PHASE4":166,"NA":168},{"trials":159,"activeCount":77},[],{"trials":161,"activeCount":77},[],{"trials":163,"activeCount":77},[],{"trials":165,"activeCount":77},[],{"trials":167,"activeCount":77},[],{"trials":169,"activeCount":73,"soonestReadout":62},[170],{"nctId":60,"briefTitle":61,"status":107,"phases":171,"primaryCompletion":62,"completion":172,"start":173,"enrollment":174,"conditions":175,"interventions":177},[70],"2029-12-31","2019-05-01",220,[15,176],"Pain, Postoperative",[63,178,179,180,181,182,183],"Esketamine","Lidocaine","Remifentanil","Desflurane","Propofol","Oxycodone",{"intervention":178,"totalTrials":73,"cells":185},{"EARLY_PHASE1":186,"PHASE1":188,"PHASE2":190,"PHASE3":192,"PHASE4":194,"NA":196},{"trials":187,"activeCount":77},[],{"trials":189,"activeCount":77},[],{"trials":191,"activeCount":77},[],{"trials":193,"activeCount":77},[],{"trials":195,"activeCount":77},[],{"trials":197,"activeCount":73,"soonestReadout":62},[198],{"nctId":60,"briefTitle":61,"status":107,"phases":199,"primaryCompletion":62,"completion":172,"start":173,"enrollment":174,"conditions":200,"interventions":201},[70],[15,176],[63,178,179,180,181,182,183],{"intervention":179,"totalTrials":73,"cells":203},{"EARLY_PHASE1":204,"PHASE1":206,"PHASE2":208,"PHASE3":210,"PHASE4":212,"NA":214},{"trials":205,"activeCount":77},[],{"trials":207,"activeCount":77},[],{"trials":209,"activeCount":77},[],{"trials":211,"activeCount":77},[],{"trials":213,"activeCount":77},[],{"trials":215,"activeCount":73,"soonestReadout":62},[216],{"nctId":60,"briefTitle":61,"status":107,"phases":217,"primaryCompletion":62,"completion":172,"start":173,"enrollment":174,"conditions":218,"interventions":219},[70],[15,176],[63,178,179,180,181,182,183],{"intervention":180,"totalTrials":73,"cells":221},{"EARLY_PHASE1":222,"PHASE1":224,"PHASE2":226,"PHASE3":228,"PHASE4":230,"NA":232},{"trials":223,"activeCount":77},[],{"trials":225,"activeCount":77},[],{"trials":227,"activeCount":77},[],{"trials":229,"activeCount":77},[],{"trials":231,"activeCount":77},[],{"trials":233,"activeCount":73,"soonestReadout":62},[234],{"nctId":60,"briefTitle":61,"status":107,"phases":235,"primaryCompletion":62,"completion":172,"start":173,"enrollment":174,"conditions":236,"interventions":237},[70],[15,176],[63,178,179,180,181,182,183],{"intervention":181,"totalTrials":73,"cells":239},{"EARLY_PHASE1":240,"PHASE1":242,"PHASE2":244,"PHASE3":246,"PHASE4":248,"NA":250},{"trials":241,"activeCount":77},[],{"trials":243,"activeCount":77},[],{"trials":245,"activeCount":77},[],{"trials":247,"activeCount":77},[],{"trials":249,"activeCount":77},[],{"trials":251,"activeCount":73,"soonestReadout":62},[252],{"nctId":60,"briefTitle":61,"status":107,"phases":253,"primaryCompletion":62,"completion":172,"start":173,"enrollment":174,"conditions":254,"interventions":255},[70],[15,176],[63,178,179,180,181,182,183],{"intervention":182,"totalTrials":73,"cells":257},{"EARLY_PHASE1":258,"PHASE1":260,"PHASE2":262,"PHASE3":264,"PHASE4":266,"NA":268},{"trials":259,"activeCount":77},[],{"trials":261,"activeCount":77},[],{"trials":263,"activeCount":77},[],{"trials":265,"activeCount":77},[],{"trials":267,"activeCount":77},[],{"trials":269,"activeCount":73,"soonestReadout":62},[270],{"nctId":60,"briefTitle":61,"status":107,"phases":271,"primaryCompletion":62,"completion":172,"start":173,"enrollment":174,"conditions":272,"interventions":273},[70],[15,176],[63,178,179,180,181,182,183],{"intervention":183,"totalTrials":73,"cells":275},{"EARLY_PHASE1":276,"PHASE1":278,"PHASE2":280,"PHASE3":282,"PHASE4":284,"NA":286},{"trials":277,"activeCount":77},[],{"trials":279,"activeCount":77},[],{"trials":281,"activeCount":77},[],{"trials":283,"activeCount":77},[],{"trials":285,"activeCount":77},[],{"trials":287,"activeCount":73,"soonestReadout":62},[288],{"nctId":60,"briefTitle":61,"status":107,"phases":289,"primaryCompletion":62,"completion":172,"start":173,"enrollment":174,"conditions":290,"interventions":291},[70],[15,176],[63,178,179,180,181,182,183],{"intervention":58,"totalTrials":73,"cells":293},{"EARLY_PHASE1":294,"PHASE1":296,"PHASE2":298,"PHASE3":300,"PHASE4":302,"NA":304},{"trials":295,"activeCount":77},[],{"trials":297,"activeCount":77},[],{"trials":299,"activeCount":77},[],{"trials":301,"activeCount":77},[],{"trials":303,"activeCount":77},[],{"trials":305,"activeCount":73,"soonestReadout":57},[306],{"nctId":55,"briefTitle":56,"status":107,"phases":307,"primaryCompletion":57,"completion":57,"start":308,"enrollment":309,"conditions":310,"interventions":312},[70],"2023-04-28",80,[311],"Primary Hyperaldosteronism Due to Adrenal Adenoma",[58],{"intervention":314,"totalTrials":315,"cells":316},"Saline",3,{"EARLY_PHASE1":317,"PHASE1":319,"PHASE2":321,"PHASE3":323,"PHASE4":337,"NA":361},{"trials":318,"activeCount":77},[],{"trials":320,"activeCount":77},[],{"trials":322,"activeCount":77},[],{"trials":324,"activeCount":77},[325],{"nctId":326,"briefTitle":327,"status":328,"phases":329,"primaryCompletion":330,"completion":330,"start":331,"enrollment":332,"conditions":333,"interventions":335},"NCT02256228","Intra-Peritoneal Local Anaesthesia After Cytoreductive Surgery","COMPLETED",[68],"2017-12","2014-10",40,[334],"Pain",[336,314],"Ropivacaine",{"trials":338,"activeCount":77},[339,350],{"nctId":340,"briefTitle":341,"status":328,"phases":342,"primaryCompletion":343,"completion":343,"start":344,"enrollment":345,"conditions":346,"interventions":347},"NCT01857804","Surgical Treatment of Peri-implantitis",[69],"2014-11","2013-01",100,[34],[348,349,314],"Amoxicillin","Chlorhexidine gluconate",{"nctId":351,"briefTitle":352,"status":353,"phases":354,"primaryCompletion":355,"completion":355,"start":356,"enrollment":357,"conditions":358,"interventions":360},"NCT03919045","Saline Injections for Prophylactic Treatment of Chronic Migraine","TERMINATED",[69],"2021-05-21","2019-06-17",10,[359],"Chronic Migraine",[314],{"trials":362,"activeCount":77},[],{"intervention":364,"totalTrials":73,"cells":365},"Insulatard, flexpen",{"EARLY_PHASE1":366,"PHASE1":368,"PHASE2":370,"PHASE3":372,"PHASE4":374,"NA":386},{"trials":367,"activeCount":77},[],{"trials":369,"activeCount":77},[],{"trials":371,"activeCount":77},[],{"trials":373,"activeCount":77},[],{"trials":375,"activeCount":77},[376],{"nctId":377,"briefTitle":378,"status":328,"phases":379,"completion":380,"start":381,"enrollment":382,"conditions":383,"interventions":385},"NCT00329615","Insulin Treatment in Cancer Cachexia",[69],"2005-09","2000-01",135,[384],"Cancer Cachexia",[364],{"trials":387,"activeCount":77},[],{"intervention":389,"totalTrials":73,"cells":390},"Antibiotic treatment (Piperacillin\u002FTazobactam, 4 gram x 3), followed by 8-10 days of out-hospital oral antibiotic treatment (Ciprofloxacin 500 mgx2,Flagyl 400 mgx3).",{"EARLY_PHASE1":391,"PHASE1":393,"PHASE2":395,"PHASE3":397,"PHASE4":399,"NA":412},{"trials":392,"activeCount":77},[],{"trials":394,"activeCount":77},[],{"trials":396,"activeCount":77},[],{"trials":398,"activeCount":77},[],{"trials":400,"activeCount":77},[401],{"nctId":402,"briefTitle":403,"status":328,"phases":404,"primaryCompletion":405,"completion":406,"start":407,"enrollment":408,"conditions":409,"interventions":411},"NCT03985514","Acute Appendicitis: Active Observation With and Without Antibiotics",[69],"2021-06-30","2022-06-30","2018-05-15",126,[410],"Appendicitis",[389],{"trials":413,"activeCount":77},[],{"intervention":415,"totalTrials":73,"cells":416},"Peg-interferon-alfa2a",{"EARLY_PHASE1":417,"PHASE1":419,"PHASE2":421,"PHASE3":423,"PHASE4":425,"NA":438},{"trials":418,"activeCount":77},[],{"trials":420,"activeCount":77},[],{"trials":422,"activeCount":77},[],{"trials":424,"activeCount":77},[],{"trials":426,"activeCount":77},[427],{"nctId":428,"briefTitle":429,"status":328,"phases":430,"primaryCompletion":431,"completion":432,"start":433,"enrollment":345,"conditions":434,"interventions":436},"NCT00910975","Individualized Duration of Peg-interferon\u002FRibavirin Treatment of Hepatitis C",[69],"2010-06","2011-09","2007-11",[435],"Chronic Hepatitis C, Genotype 1",[415,437],"Ribavirin",{"trials":439,"activeCount":77},[],{"intervention":437,"totalTrials":73,"cells":441},{"EARLY_PHASE1":442,"PHASE1":444,"PHASE2":446,"PHASE3":448,"PHASE4":450,"NA":456},{"trials":443,"activeCount":77},[],{"trials":445,"activeCount":77},[],{"trials":447,"activeCount":77},[],{"trials":449,"activeCount":77},[],{"trials":451,"activeCount":77},[452],{"nctId":428,"briefTitle":429,"status":328,"phases":453,"primaryCompletion":431,"completion":432,"start":433,"enrollment":345,"conditions":454,"interventions":455},[69],[435],[415,437],{"trials":457,"activeCount":77},[],{"intervention":459,"totalTrials":73,"cells":460},"Pegylated interferon alfa-2a and ribavirin",{"EARLY_PHASE1":461,"PHASE1":463,"PHASE2":465,"PHASE3":467,"PHASE4":469,"NA":481},{"trials":462,"activeCount":77},[],{"trials":464,"activeCount":77},[],{"trials":466,"activeCount":77},[],{"trials":468,"activeCount":77},[],{"trials":470,"activeCount":77},[471],{"nctId":472,"briefTitle":473,"status":353,"phases":474,"primaryCompletion":475,"completion":475,"start":476,"enrollment":477,"conditions":478,"interventions":480},"NCT00641654","Combination Therapy With Pegylated Interferon and Ribavirin in Patients With Chronic Hepatitis C Genotype 2 or 3 Infection Who Previously Have Relapsed After Therapy With Pegylated Interferon and Ribavirin",[69],"2009-12","2007-01",75,[479],"Chronic Hepatitis C",[459,459,459],{"trials":482,"activeCount":77},[],{"intervention":484,"totalTrials":73,"cells":485},"Betamethasone",{"EARLY_PHASE1":486,"PHASE1":488,"PHASE2":490,"PHASE3":492,"PHASE4":494,"NA":507},{"trials":487,"activeCount":77},[],{"trials":489,"activeCount":77},[],{"trials":491,"activeCount":77},[],{"trials":493,"activeCount":77},[],{"trials":495,"activeCount":77},[496],{"nctId":497,"briefTitle":498,"status":328,"phases":499,"primaryCompletion":500,"completion":501,"start":502,"enrollment":503,"conditions":504,"interventions":506},"NCT03210545","A Study of Markers of Glucocorticoid Effects in Patients With Addisons Disease (DOSCORT)",[69],"2021-11-09","2022-02-16","2021-03-02",30,[505],"Addison Disease",[484],{"trials":508,"activeCount":77},[],{"intervention":348,"totalTrials":73,"cells":510},{"EARLY_PHASE1":511,"PHASE1":513,"PHASE2":515,"PHASE3":517,"PHASE4":519,"NA":525},{"trials":512,"activeCount":77},[],{"trials":514,"activeCount":77},[],{"trials":516,"activeCount":77},[],{"trials":518,"activeCount":77},[],{"trials":520,"activeCount":77},[521],{"nctId":340,"briefTitle":341,"status":328,"phases":522,"primaryCompletion":343,"completion":343,"start":344,"enrollment":345,"conditions":523,"interventions":524},[69],[34],[348,349,314],{"trials":526,"activeCount":77},[],{"intervention":349,"totalTrials":73,"cells":528},{"EARLY_PHASE1":529,"PHASE1":531,"PHASE2":533,"PHASE3":535,"PHASE4":537,"NA":543},{"trials":530,"activeCount":77},[],{"trials":532,"activeCount":77},[],{"trials":534,"activeCount":77},[],{"trials":536,"activeCount":77},[],{"trials":538,"activeCount":77},[539],{"nctId":340,"briefTitle":341,"status":328,"phases":540,"primaryCompletion":343,"completion":343,"start":344,"enrollment":345,"conditions":541,"interventions":542},[69],[34],[348,349,314],{"trials":544,"activeCount":77},[],{"intervention":546,"totalTrials":73,"cells":547},"Indomethacin, celecoxib, esomeprazole",{"EARLY_PHASE1":548,"PHASE1":550,"PHASE2":552,"PHASE3":554,"PHASE4":556,"NA":568},{"trials":549,"activeCount":77},[],{"trials":551,"activeCount":77},[],{"trials":553,"activeCount":77},[],{"trials":555,"activeCount":77},[],{"trials":557,"activeCount":77},[558],{"nctId":559,"briefTitle":560,"status":328,"phases":561,"completion":562,"start":563,"enrollment":564,"conditions":565,"interventions":567},"NCT00473980","Preoperative Non-steroidal Anti-inflammatory Drugs(NSAID) to Colorectal Cancer Patients",[69],"2007-05","1998-12",28,[566],"Colorectal Cancer",[546],{"trials":569,"activeCount":77},[],{"intervention":571,"totalTrials":73,"cells":572},"ADHD medications",{"EARLY_PHASE1":573,"PHASE1":575,"PHASE2":577,"PHASE3":579,"PHASE4":581,"NA":593},{"trials":574,"activeCount":77},[],{"trials":576,"activeCount":77},[],{"trials":578,"activeCount":77},[],{"trials":580,"activeCount":77},[],{"trials":582,"activeCount":77},[583],{"nctId":584,"briefTitle":585,"status":328,"phases":586,"primaryCompletion":587,"completion":587,"start":588,"enrollment":589,"conditions":590,"interventions":592},"NCT03250013","Long-term Effects of Medication for ADHD",[69],"2022-01-30","2014-04",128,[591],"Attention Deficit Disorder With Hyperactivity",[571],{"trials":594,"activeCount":77},[],{"intervention":596,"totalTrials":73,"cells":597},"TAF\u002FFTC",{"EARLY_PHASE1":598,"PHASE1":600,"PHASE2":602,"PHASE3":604,"PHASE4":606,"NA":617},{"trials":599,"activeCount":77},[],{"trials":601,"activeCount":77},[],{"trials":603,"activeCount":77},[],{"trials":605,"activeCount":77},[],{"trials":607,"activeCount":77},[608],{"nctId":609,"briefTitle":610,"status":328,"phases":611,"primaryCompletion":612,"completion":612,"start":613,"enrollment":111,"conditions":614,"interventions":616},"NCT02771054","Tenofovir Alafenamide Fumarate (TAF) Effect on Residual Intrathecal Immune Activation",[69],"2018-07-15","2016-05-02",[615],"HIV",[596],{"trials":618,"activeCount":77},[],{"intervention":620,"totalTrials":73,"cells":621},"Lopinavir ritonavir",{"EARLY_PHASE1":622,"PHASE1":624,"PHASE2":626,"PHASE3":628,"PHASE4":630,"NA":642},{"trials":623,"activeCount":77},[],{"trials":625,"activeCount":77},[],{"trials":627,"activeCount":77},[],{"trials":629,"activeCount":77},[],{"trials":631,"activeCount":77},[632],{"nctId":633,"briefTitle":634,"status":328,"phases":635,"primaryCompletion":475,"completion":475,"start":636,"enrollment":637,"conditions":638,"interventions":639},"NCT01445223","A Study on Antiretroviral Therapy (ART) Naïve Patients On Different Regimens to Treat Hiv (NORTHIV)",[69],"2004-04",242,[615],[620,640,641],"Atazanavir ritonavir","Efavirenz",{"trials":643,"activeCount":77},[],{"intervention":640,"totalTrials":73,"cells":645},{"EARLY_PHASE1":646,"PHASE1":648,"PHASE2":650,"PHASE3":652,"PHASE4":654,"NA":660},{"trials":647,"activeCount":77},[],{"trials":649,"activeCount":77},[],{"trials":651,"activeCount":77},[],{"trials":653,"activeCount":77},[],{"trials":655,"activeCount":77},[656],{"nctId":633,"briefTitle":634,"status":328,"phases":657,"primaryCompletion":475,"completion":475,"start":636,"enrollment":637,"conditions":658,"interventions":659},[69],[615],[620,640,641],{"trials":661,"activeCount":77},[],{"intervention":641,"totalTrials":73,"cells":663},{"EARLY_PHASE1":664,"PHASE1":666,"PHASE2":668,"PHASE3":670,"PHASE4":672,"NA":678},{"trials":665,"activeCount":77},[],{"trials":667,"activeCount":77},[],{"trials":669,"activeCount":77},[],{"trials":671,"activeCount":77},[],{"trials":673,"activeCount":77},[674],{"nctId":633,"briefTitle":634,"status":328,"phases":675,"primaryCompletion":475,"completion":475,"start":636,"enrollment":637,"conditions":676,"interventions":677},[69],[615],[620,640,641],{"trials":679,"activeCount":77},[],{"intervention":681,"totalTrials":73,"cells":682},"Rituximab",{"EARLY_PHASE1":683,"PHASE1":685,"PHASE2":687,"PHASE3":689,"PHASE4":691,"NA":706},{"trials":684,"activeCount":77},[],{"trials":686,"activeCount":77},[],{"trials":688,"activeCount":77},[],{"trials":690,"activeCount":77},[],{"trials":692,"activeCount":77},[693],{"nctId":694,"briefTitle":695,"status":328,"phases":696,"primaryCompletion":697,"completion":698,"start":699,"enrollment":700,"conditions":701,"interventions":703},"NCT02378298","Rituximab (RTX) Therapy in Patients With Active TAO",[69],"2019-09-03","2020-02-01","2011-12",38,[702],"Ophthalmopathy, Thyroid-Associated",[681,704,705],"Iv Methylprednisolone","peroral methylprednisolone and Methotrexate",{"trials":707,"activeCount":77},[],{"intervention":704,"totalTrials":73,"cells":709},{"EARLY_PHASE1":710,"PHASE1":712,"PHASE2":714,"PHASE3":716,"PHASE4":718,"NA":724},{"trials":711,"activeCount":77},[],{"trials":713,"activeCount":77},[],{"trials":715,"activeCount":77},[],{"trials":717,"activeCount":77},[],{"trials":719,"activeCount":77},[720],{"nctId":694,"briefTitle":695,"status":328,"phases":721,"primaryCompletion":697,"completion":698,"start":699,"enrollment":700,"conditions":722,"interventions":723},[69],[702],[681,704,705],{"trials":725,"activeCount":77},[],{"intervention":705,"totalTrials":73,"cells":727},{"EARLY_PHASE1":728,"PHASE1":730,"PHASE2":732,"PHASE3":734,"PHASE4":736,"NA":742},{"trials":729,"activeCount":77},[],{"trials":731,"activeCount":77},[],{"trials":733,"activeCount":77},[],{"trials":735,"activeCount":77},[],{"trials":737,"activeCount":77},[738],{"nctId":694,"briefTitle":695,"status":328,"phases":739,"primaryCompletion":697,"completion":698,"start":699,"enrollment":700,"conditions":740,"interventions":741},[69],[702],[681,704,705],{"trials":743,"activeCount":77},[],{"intervention":745,"totalTrials":98,"cells":746},"Levosimendan",{"EARLY_PHASE1":747,"PHASE1":749,"PHASE2":751,"PHASE3":764,"PHASE4":776,"NA":778},{"trials":748,"activeCount":77},[],{"trials":750,"activeCount":77},[],{"trials":752,"activeCount":77},[753],{"nctId":754,"briefTitle":755,"status":328,"phases":756,"primaryCompletion":757,"completion":757,"start":758,"enrollment":759,"conditions":760,"interventions":762},"NCT02232399","Is Levosimendan Superior to Milrinone Regarding Acute Kidney Injury After Cardiac Surgery for Congenital Heart Disease?",[67],"2017-04-25","2014-10-15",72,[761],"Congenital Heart Defects",[745,763],"Milrinone",{"trials":765,"activeCount":77},[766],{"nctId":767,"briefTitle":768,"status":328,"phases":769,"primaryCompletion":770,"completion":770,"start":588,"enrollment":771,"conditions":772,"interventions":774},"NCT02133105","Levosimendan Versus Dobutamine for Renal Function in Heart Failure",[68],"2017-05",33,[773],"Cardiorenal Syndrome",[745,775],"Dobutamine",{"trials":777,"activeCount":77},[],{"trials":779,"activeCount":77},[],{"intervention":781,"totalTrials":73,"cells":782},"Ribavirin \"loading\" dose given",{"EARLY_PHASE1":783,"PHASE1":785,"PHASE2":787,"PHASE3":789,"PHASE4":803,"NA":805},{"trials":784,"activeCount":77},[],{"trials":786,"activeCount":77},[],{"trials":788,"activeCount":77},[],{"trials":790,"activeCount":77},[791],{"nctId":792,"briefTitle":793,"status":328,"phases":794,"primaryCompletion":795,"completion":795,"start":796,"enrollment":797,"conditions":798,"interventions":800},"NCT01226771","Ribavirin Loading Dose or Priming and Concentration Targeting for HCV Genotype 1",[68],"2014-09","2010-09",105,[799],"Hepatitis C",[781,801,802],"\"Priming\" dose of ribavirin given","Group C",{"trials":804,"activeCount":77},[],{"trials":806,"activeCount":77},[],{"intervention":801,"totalTrials":73,"cells":808},{"EARLY_PHASE1":809,"PHASE1":811,"PHASE2":813,"PHASE3":815,"PHASE4":821,"NA":823},{"trials":810,"activeCount":77},[],{"trials":812,"activeCount":77},[],{"trials":814,"activeCount":77},[],{"trials":816,"activeCount":77},[817],{"nctId":792,"briefTitle":793,"status":328,"phases":818,"primaryCompletion":795,"completion":795,"start":796,"enrollment":797,"conditions":819,"interventions":820},[68],[799],[781,801,802],{"trials":822,"activeCount":77},[],{"trials":824,"activeCount":77},[],{"intervention":802,"totalTrials":73,"cells":826},{"EARLY_PHASE1":827,"PHASE1":829,"PHASE2":831,"PHASE3":833,"PHASE4":839,"NA":841},{"trials":828,"activeCount":77},[],{"trials":830,"activeCount":77},[],{"trials":832,"activeCount":77},[],{"trials":834,"activeCount":77},[835],{"nctId":792,"briefTitle":793,"status":328,"phases":836,"primaryCompletion":795,"completion":795,"start":796,"enrollment":797,"conditions":837,"interventions":838},[68],[799],[781,801,802],{"trials":840,"activeCount":77},[],{"trials":842,"activeCount":77},[],{"intervention":775,"totalTrials":73,"cells":844},{"EARLY_PHASE1":845,"PHASE1":847,"PHASE2":849,"PHASE3":851,"PHASE4":857,"NA":859},{"trials":846,"activeCount":77},[],{"trials":848,"activeCount":77},[],{"trials":850,"activeCount":77},[],{"trials":852,"activeCount":77},[853],{"nctId":767,"briefTitle":768,"status":328,"phases":854,"primaryCompletion":770,"completion":770,"start":588,"enrollment":771,"conditions":855,"interventions":856},[68],[773],[745,775],{"trials":858,"activeCount":77},[],{"trials":860,"activeCount":77},[],{"intervention":862,"totalTrials":73,"cells":863},"recombinant human growth hormone",{"EARLY_PHASE1":864,"PHASE1":866,"PHASE2":868,"PHASE3":870,"PHASE4":883,"NA":885},{"trials":865,"activeCount":77},[],{"trials":867,"activeCount":77},[],{"trials":869,"activeCount":77},[],{"trials":871,"activeCount":77},[872],{"nctId":873,"briefTitle":874,"status":328,"phases":875,"primaryCompletion":876,"completion":877,"start":878,"enrollment":332,"conditions":879,"interventions":882},"NCT00781547","Growth Hormone Treatment in Men With High Risk of Developing Type 2 Diabetes Mellitus",[68],"2003-09","2005-05","1999-01",[880,881,15],"Abdominal Obesity","Metabolic Syndrome",[862],{"trials":884,"activeCount":77},[],{"trials":886,"activeCount":77},[],{"intervention":888,"totalTrials":73,"cells":889},"ropivacaine, ketorelac and epinephrine",{"EARLY_PHASE1":890,"PHASE1":892,"PHASE2":894,"PHASE3":896,"PHASE4":905,"NA":907},{"trials":891,"activeCount":77},[],{"trials":893,"activeCount":77},[],{"trials":895,"activeCount":77},[],{"trials":897,"activeCount":77},[898],{"nctId":899,"briefTitle":900,"status":328,"phases":901,"primaryCompletion":331,"completion":331,"start":902,"enrollment":91,"conditions":903,"interventions":904},"NCT01782781","Local Infiltration Analgesia After Abdominal Hysterectomy",[68],"2012-11",[334],[888],{"trials":906,"activeCount":77},[],{"trials":908,"activeCount":77},[],{"intervention":910,"totalTrials":73,"cells":911},"Gallium-68 DOTATOC PET",{"EARLY_PHASE1":912,"PHASE1":914,"PHASE2":916,"PHASE3":918,"PHASE4":929,"NA":931},{"trials":913,"activeCount":77},[],{"trials":915,"activeCount":77},[],{"trials":917,"activeCount":77},[],{"trials":919,"activeCount":77},[920],{"nctId":921,"briefTitle":922,"status":353,"phases":923,"primaryCompletion":924,"completion":924,"start":925,"enrollment":111,"conditions":926,"interventions":928},"NCT02419664","Ga-68-DOTATOC -PET in the Management of Pituitary Tumours",[68],"2022-01-13","2015-01",[927],"Pituitary Tumours",[910],{"trials":930,"activeCount":77},[],{"trials":932,"activeCount":77},[],{"intervention":934,"totalTrials":73,"cells":935},"Ghrelin",{"EARLY_PHASE1":936,"PHASE1":938,"PHASE2":940,"PHASE3":942,"PHASE4":954,"NA":956},{"trials":937,"activeCount":77},[],{"trials":939,"activeCount":77},[],{"trials":941,"activeCount":77},[],{"trials":943,"activeCount":77},[944],{"nctId":945,"briefTitle":946,"status":328,"phases":947,"primaryCompletion":948,"completion":949,"start":950,"enrollment":503,"conditions":951,"interventions":953},"NCT00681486","Ghrelin - A Possible Opportunity to Improve Appetite",[68],"2008-06","2008-07","2003-10",[952],"Cancer",[934,934],{"trials":955,"activeCount":77},[],{"trials":957,"activeCount":77},[],{"intervention":959,"totalTrials":73,"cells":960},"Hyperbaric Oxygen",{"EARLY_PHASE1":961,"PHASE1":963,"PHASE2":965,"PHASE3":967,"PHASE4":978,"NA":980},{"trials":962,"activeCount":77},[],{"trials":964,"activeCount":77},[],{"trials":966,"activeCount":77},[],{"trials":968,"activeCount":77},[969],{"nctId":970,"briefTitle":971,"status":328,"phases":972,"primaryCompletion":973,"completion":973,"start":974,"enrollment":477,"conditions":975,"interventions":977},"NCT01659723","Radiation Induced Cystitis Treated With Hyperbaric Oxygen - A Randomized Controlled Trial",[67,68],"2018-08-09","2012-08",[976],"Cystitis, Radio Induced",[959],{"trials":979,"activeCount":77},[],{"trials":981,"activeCount":77},[],{"intervention":336,"totalTrials":73,"cells":983},{"EARLY_PHASE1":984,"PHASE1":986,"PHASE2":988,"PHASE3":990,"PHASE4":996,"NA":998},{"trials":985,"activeCount":77},[],{"trials":987,"activeCount":77},[],{"trials":989,"activeCount":77},[],{"trials":991,"activeCount":77},[992],{"nctId":326,"briefTitle":327,"status":328,"phases":993,"primaryCompletion":330,"completion":330,"start":331,"enrollment":332,"conditions":994,"interventions":995},[68],[334],[336,314],{"trials":997,"activeCount":77},[],{"trials":999,"activeCount":77},[],{"intervention":1001,"totalTrials":73,"cells":1002},"Genotropin",{"EARLY_PHASE1":1003,"PHASE1":1005,"PHASE2":1007,"PHASE3":1009,"PHASE4":1021,"NA":1023},{"trials":1004,"activeCount":77},[],{"trials":1006,"activeCount":77},[],{"trials":1008,"activeCount":77},[],{"trials":1010,"activeCount":77},[1011],{"nctId":1012,"briefTitle":1013,"status":328,"phases":1014,"primaryCompletion":1015,"completion":330,"start":1016,"enrollment":1017,"conditions":1018,"interventions":1020},"NCT02879747","Individualizing Dose of Growth Hormone to Maintain Normal Growth Velocity After Fulfilled Catch up Growth in Children",[67,68],"2012-03","2003-12",99,[1019],"Short Stature",[1001],{"trials":1022,"activeCount":77},[],{"trials":1024,"activeCount":77},[],{"intervention":1026,"totalTrials":73,"cells":1027},"Antiandrogen",{"EARLY_PHASE1":1028,"PHASE1":1030,"PHASE2":1032,"PHASE3":1034,"PHASE4":1048,"NA":1050},{"trials":1029,"activeCount":77},[],{"trials":1031,"activeCount":77},[],{"trials":1033,"activeCount":77},[],{"trials":1035,"activeCount":77},[1036],{"nctId":1037,"briefTitle":1038,"status":1039,"phases":1040,"primaryCompletion":1041,"completion":1041,"start":1042,"enrollment":1043,"conditions":1044,"interventions":1046},"NCT03119857","Early Rising PSA Endocrine Treatment Versus Chemo-endocrine Therapy- SPCG14","UNKNOWN",[68],"2023-04","2009-02",349,[1045],"Prostatic Neoplasms",[1026,1047],"Antiandrogen+docetaxel",{"trials":1049,"activeCount":77},[],{"trials":1051,"activeCount":77},[],{"intervention":1047,"totalTrials":73,"cells":1053},{"EARLY_PHASE1":1054,"PHASE1":1056,"PHASE2":1058,"PHASE3":1060,"PHASE4":1066,"NA":1068},{"trials":1055,"activeCount":77},[],{"trials":1057,"activeCount":77},[],{"trials":1059,"activeCount":77},[],{"trials":1061,"activeCount":77},[1062],{"nctId":1037,"briefTitle":1038,"status":1039,"phases":1063,"primaryCompletion":1041,"completion":1041,"start":1042,"enrollment":1043,"conditions":1064,"interventions":1065},[68],[1045],[1026,1047],{"trials":1067,"activeCount":77},[],{"trials":1069,"activeCount":77},[],{"intervention":1071,"totalTrials":73,"cells":1072},"Somatropin",{"EARLY_PHASE1":1073,"PHASE1":1075,"PHASE2":1077,"PHASE3":1079,"PHASE4":1092,"NA":1094},{"trials":1074,"activeCount":77},[],{"trials":1076,"activeCount":77},[],{"trials":1078,"activeCount":77},[],{"trials":1080,"activeCount":77},[1081],{"nctId":1082,"briefTitle":1083,"status":328,"phases":1084,"primaryCompletion":1085,"completion":1085,"start":1086,"enrollment":1087,"conditions":1088,"interventions":1091},"NCT04420481","Growth Hormone in Ischemic Heart Failure",[68],"2012-02-25","2004-04-28",37,[1089,1090],"Heart Failure, Systolic","Ischemic Heart Disease Chronic",[1071],{"trials":1093,"activeCount":77},[],{"trials":1095,"activeCount":77},[],{"intervention":1097,"totalTrials":73,"cells":1098},"Oxygen",{"EARLY_PHASE1":1099,"PHASE1":1101,"PHASE2":1103,"PHASE3":1105,"PHASE4":1121,"NA":1123},{"trials":1100,"activeCount":77},[],{"trials":1102,"activeCount":77},[],{"trials":1104,"activeCount":77},[],{"trials":1106,"activeCount":77},[1107],{"nctId":1108,"briefTitle":1109,"status":328,"phases":1110,"primaryCompletion":1111,"completion":1111,"start":1112,"enrollment":1113,"conditions":1114,"interventions":1120},"NCT02468752","Reduction of Venous Emboli Load After Breathing Normobaric Oxygen Compared to Air",[67,68],"2019-04","2015-05",48,[1115,1116,1117,1118,32,1119],"Hyperbaric","Diving Medicine","Decompression Sickness","Central Nervous Injury","Endothelial Dysfunction",[1097],{"trials":1122,"activeCount":77},[],{"trials":1124,"activeCount":77},[],{"intervention":1126,"totalTrials":73,"cells":1127},"Rosuvastatin",{"EARLY_PHASE1":1128,"PHASE1":1130,"PHASE2":1132,"PHASE3":1134,"PHASE4":1146,"NA":1148},{"trials":1129,"activeCount":77},[],{"trials":1131,"activeCount":77},[],{"trials":1133,"activeCount":77},[],{"trials":1135,"activeCount":77},[1136],{"nctId":1137,"briefTitle":1138,"status":328,"phases":1139,"primaryCompletion":1140,"completion":1141,"start":1142,"enrollment":1143,"conditions":1144,"interventions":1145},"NCT01068626","Rosuvastatin in Visceral Adiposity",[68],"2008-10","2008-12","2006-05",54,[880],[1126],{"trials":1147,"activeCount":77},[],{"trials":1149,"activeCount":77},[],{"intervention":1151,"totalTrials":73,"cells":1152},"Privigen Injectable Product",{"EARLY_PHASE1":1153,"PHASE1":1155,"PHASE2":1157,"PHASE3":1168,"PHASE4":1170,"NA":1172},{"trials":1154,"activeCount":77},[],{"trials":1156,"activeCount":77},[],{"trials":1158,"activeCount":77},[1159],{"nctId":1160,"briefTitle":1161,"status":328,"phases":1162,"primaryCompletion":1163,"completion":1163,"start":1164,"enrollment":9,"conditions":1165,"interventions":1167},"NCT04609761","Open-label Trial of IVIG in Children With PANS",[67],"2025-10-15","2021-01-12",[1166],"PANS Pediatric Acute-Onset Neuropsychiatric Syndrome",[1151],{"trials":1169,"activeCount":77},[],{"trials":1171,"activeCount":77},[],{"trials":1173,"activeCount":77},[],{"intervention":763,"totalTrials":73,"cells":1175},{"EARLY_PHASE1":1176,"PHASE1":1178,"PHASE2":1180,"PHASE3":1186,"PHASE4":1188,"NA":1190},{"trials":1177,"activeCount":77},[],{"trials":1179,"activeCount":77},[],{"trials":1181,"activeCount":77},[1182],{"nctId":754,"briefTitle":755,"status":328,"phases":1183,"primaryCompletion":757,"completion":757,"start":758,"enrollment":759,"conditions":1184,"interventions":1185},[67],[761],[745,763],{"trials":1187,"activeCount":77},[],{"trials":1189,"activeCount":77},[],{"trials":1191,"activeCount":77},[],{"intervention":1193,"totalTrials":73,"cells":1194},"Zonisamide",{"EARLY_PHASE1":1195,"PHASE1":1197,"PHASE2":1199,"PHASE3":1212,"PHASE4":1214,"NA":1216},{"trials":1196,"activeCount":77},[],{"trials":1198,"activeCount":77},[],{"trials":1200,"activeCount":77},[1201],{"nctId":1202,"briefTitle":1203,"status":328,"phases":1204,"primaryCompletion":1205,"completion":1205,"start":1206,"enrollment":1207,"conditions":1208,"interventions":1211},"NCT01765608","Zonisamide for the Treatment of Obstructive Sleep Apnea in Overweight\u002FObese Patients",[67],"2013-06","2010-03",50,[1209,1210,15],"Sleep Apnea","Obstructive Sleep Apnea",[1193],{"trials":1213,"activeCount":77},[],{"trials":1215,"activeCount":77},[],{"trials":1217,"activeCount":77},[],{"intervention":1219,"totalTrials":73,"cells":1220},"Acetazolamide",{"EARLY_PHASE1":1221,"PHASE1":1223,"PHASE2":1225,"PHASE3":1238,"PHASE4":1240,"NA":1242},{"trials":1222,"activeCount":77},[],{"trials":1224,"activeCount":77},[],{"trials":1226,"activeCount":77},[1227],{"nctId":1228,"briefTitle":1229,"status":328,"phases":1230,"primaryCompletion":1231,"completion":1231,"start":1232,"enrollment":1233,"conditions":1234,"interventions":1237},"NCT02220803","A Short Term Open, Randomized Cross-over Trial Exploring the Effect of Carbonic Anhydrase Inhibition by Acetazolamide on Sleep Apnea Associated Hypertension and Vascular Dysfunction",[67],"2016-08","2014-03",13,[1210,1235,1236,21],"Sleep-Disordered Breathing","Blood Pressure",[1219],{"trials":1239,"activeCount":77},[],{"trials":1241,"activeCount":77},[],{"trials":1243,"activeCount":77},[],{"intervention":1245,"totalTrials":73,"cells":1246},"Tadalafil",{"EARLY_PHASE1":1247,"PHASE1":1249,"PHASE2":1251,"PHASE3":1263,"PHASE4":1265,"NA":1267},{"trials":1248,"activeCount":77},[],{"trials":1250,"activeCount":77},[],{"trials":1252,"activeCount":77},[1253],{"nctId":1254,"briefTitle":1255,"status":328,"phases":1256,"primaryCompletion":1257,"completion":1257,"start":1258,"enrollment":1259,"conditions":1260,"interventions":1262},"NCT02601989","Effects on Insulin Resistance With Tadalafil in Type 2 Diabetes - a Double-blind, Placebo-controlled Crossover Study",[67],"2019-01","2015-11",23,[1261],"Diabetes Mellitus, Type 2",[1245],{"trials":1264,"activeCount":77},[],{"trials":1266,"activeCount":77},[],{"trials":1268,"activeCount":77},[],{"intervention":1270,"totalTrials":73,"cells":1271},"Cyanocobalamin",{"EARLY_PHASE1":1272,"PHASE1":1274,"PHASE2":1276,"PHASE3":1288,"PHASE4":1290,"NA":1292},{"trials":1273,"activeCount":77},[],{"trials":1275,"activeCount":77},[],{"trials":1277,"activeCount":77},[1278],{"nctId":1279,"briefTitle":1280,"status":1039,"phases":1281,"primaryCompletion":1282,"completion":1282,"start":1283,"enrollment":91,"conditions":1284,"interventions":1285},"NCT02773147","Effect of Vitamin B on Plasma Neurofilament Light Protein (NFL) in HIV-infected Individuals With Increased Plasma Homocysteine",[67],"2018-11","2016-04",[615],[1270,1286,1287],"Folate","Pyridoxine",{"trials":1289,"activeCount":77},[],{"trials":1291,"activeCount":77},[],{"trials":1293,"activeCount":77},[],{"intervention":1286,"totalTrials":73,"cells":1295},{"EARLY_PHASE1":1296,"PHASE1":1298,"PHASE2":1300,"PHASE3":1306,"PHASE4":1308,"NA":1310},{"trials":1297,"activeCount":77},[],{"trials":1299,"activeCount":77},[],{"trials":1301,"activeCount":77},[1302],{"nctId":1279,"briefTitle":1280,"status":1039,"phases":1303,"primaryCompletion":1282,"completion":1282,"start":1283,"enrollment":91,"conditions":1304,"interventions":1305},[67],[615],[1270,1286,1287],{"trials":1307,"activeCount":77},[],{"trials":1309,"activeCount":77},[],{"trials":1311,"activeCount":77},[],{"intervention":1287,"totalTrials":73,"cells":1313},{"EARLY_PHASE1":1314,"PHASE1":1316,"PHASE2":1318,"PHASE3":1324,"PHASE4":1326,"NA":1328},{"trials":1315,"activeCount":77},[],{"trials":1317,"activeCount":77},[],{"trials":1319,"activeCount":77},[1320],{"nctId":1279,"briefTitle":1280,"status":1039,"phases":1321,"primaryCompletion":1282,"completion":1282,"start":1283,"enrollment":91,"conditions":1322,"interventions":1323},[67],[615],[1270,1286,1287],{"trials":1325,"activeCount":77},[],{"trials":1327,"activeCount":77},[],{"trials":1329,"activeCount":77},[],{"intervention":1331,"totalTrials":73,"cells":1332},"cefotaxim and metronidazol",{"EARLY_PHASE1":1333,"PHASE1":1335,"PHASE2":1337,"PHASE3":1347,"PHASE4":1349,"NA":1351},{"trials":1334,"activeCount":77},[],{"trials":1336,"activeCount":77},[],{"trials":1338,"activeCount":77},[1339],{"nctId":1340,"briefTitle":1341,"status":328,"phases":1342,"primaryCompletion":1343,"completion":1140,"start":1142,"enrollment":1344,"conditions":1345,"interventions":1346},"NCT00469430","Study of Conservative Versus Surgical Treatment of Appendicitis",[67],"2007-09",360,[410],[1331],{"trials":1348,"activeCount":77},[],{"trials":1350,"activeCount":77},[],{"trials":1352,"activeCount":77},[],{"intervention":1354,"totalTrials":73,"cells":1355},"postprandial plasma glucose",{"EARLY_PHASE1":1356,"PHASE1":1358,"PHASE2":1360,"PHASE3":1369,"PHASE4":1371,"NA":1373},{"trials":1357,"activeCount":77},[],{"trials":1359,"activeCount":77},[],{"trials":1361,"activeCount":77},[1362],{"nctId":1363,"briefTitle":1364,"status":328,"phases":1365,"primaryCompletion":1232,"completion":1232,"start":1343,"enrollment":1207,"conditions":1366,"interventions":1368},"NCT01557296","Evaluation of Diagnostic Methods and Dietary Treatment of Diabetic Gastroparesis",[67],[1367],"Diabetic Gastroparesis",[1354],{"trials":1370,"activeCount":77},[],{"trials":1372,"activeCount":77},[],{"trials":1374,"activeCount":77},[],{"intervention":1376,"totalTrials":73,"cells":1377},"VSL#3",{"EARLY_PHASE1":1378,"PHASE1":1389,"PHASE2":1391,"PHASE3":1393,"PHASE4":1395,"NA":1397},{"trials":1379,"activeCount":77},[1380],{"nctId":1381,"briefTitle":1382,"status":328,"phases":1383,"primaryCompletion":1384,"completion":1384,"start":699,"enrollment":1385,"conditions":1386,"interventions":1388},"NCT01635192","Effects of Probiotic VSL#3 on Expression of Small Intestinal Renin-angiotensin System",[65],"2013-07",24,[1387],"the Local Renin-angiotensin System (RAS) in Small Intestinal Mucosa in Man",[1376],{"trials":1390,"activeCount":77},[],{"trials":1392,"activeCount":77},[],{"trials":1394,"activeCount":77},[],{"trials":1396,"activeCount":77},[],{"trials":1398,"activeCount":77},[],{"intervention":1400,"totalTrials":73,"cells":1401},"Candesartan",{"EARLY_PHASE1":1402,"PHASE1":1414,"PHASE2":1416,"PHASE3":1418,"PHASE4":1420,"NA":1422},{"trials":1403,"activeCount":77},[1404],{"nctId":1405,"briefTitle":1406,"status":328,"phases":1407,"primaryCompletion":1408,"completion":1408,"start":1409,"enrollment":771,"conditions":1410,"interventions":1412},"NCT02879721","Expression and Function of the Renin-Angiotensin System in the Esophagus",[65],"2012-12","2009-10",[1411],"Barrett's Esophagus",[1400,1413],"Enalapril",{"trials":1415,"activeCount":77},[],{"trials":1417,"activeCount":77},[],{"trials":1419,"activeCount":77},[],{"trials":1421,"activeCount":77},[],{"trials":1423,"activeCount":77},[],{"intervention":1413,"totalTrials":73,"cells":1425},{"EARLY_PHASE1":1426,"PHASE1":1432,"PHASE2":1434,"PHASE3":1436,"PHASE4":1438,"NA":1440},{"trials":1427,"activeCount":77},[1428],{"nctId":1405,"briefTitle":1406,"status":328,"phases":1429,"primaryCompletion":1408,"completion":1408,"start":1409,"enrollment":771,"conditions":1430,"interventions":1431},[65],[1411],[1400,1413],{"trials":1433,"activeCount":77},[],{"trials":1435,"activeCount":77},[],{"trials":1437,"activeCount":77},[],{"trials":1439,"activeCount":77},[],{"trials":1441,"activeCount":77},[],{"intervention":1443,"totalTrials":73,"cells":1444},"Oxytocin",{"EARLY_PHASE1":1445,"PHASE1":1447,"PHASE2":1449,"PHASE3":1451,"PHASE4":1453,"NA":1455},{"trials":1446,"activeCount":77},[],{"trials":1448,"activeCount":77},[],{"trials":1450,"activeCount":77},[],{"trials":1452,"activeCount":77},[],{"trials":1454,"activeCount":77},[],{"trials":1456,"activeCount":77},[1457],{"nctId":1458,"briefTitle":1459,"status":328,"phases":1460,"primaryCompletion":1461,"completion":1462,"start":1463,"enrollment":1464,"conditions":1465,"interventions":1467},"NCT01587625","High Dose Versus Low Dose Oxytocin for Augmentation of Delayed Labour",[70],"2016-06-09","2016-10-08","2013-08",1376,[1466],"Birth; Delayed",[1443],{"intervention":1469,"totalTrials":73,"cells":1470},"L-lysine",{"EARLY_PHASE1":1471,"PHASE1":1473,"PHASE2":1475,"PHASE3":1477,"PHASE4":1479,"NA":1481},{"trials":1472,"activeCount":77},[],{"trials":1474,"activeCount":77},[],{"trials":1476,"activeCount":77},[],{"trials":1478,"activeCount":77},[],{"trials":1480,"activeCount":77},[],{"trials":1482,"activeCount":77},[1483],{"nctId":1484,"briefTitle":1485,"status":328,"phases":1486,"primaryCompletion":1487,"completion":1488,"start":1343,"enrollment":357,"conditions":1489,"interventions":1491},"NCT00996242","An Exploratory Open Label Study of Adjunctive L-lysine Treatment in Patients With Schizophrenia",[70],"2008-09","2009-03",[1490],"Schizophrenia",[1469],{"intervention":1493,"totalTrials":73,"cells":1494},"iv opioid",{"EARLY_PHASE1":1495,"PHASE1":1497,"PHASE2":1499,"PHASE3":1501,"PHASE4":1503,"NA":1505},{"trials":1496,"activeCount":77},[],{"trials":1498,"activeCount":77},[],{"trials":1500,"activeCount":77},[],{"trials":1502,"activeCount":77},[],{"trials":1504,"activeCount":77},[],{"trials":1506,"activeCount":77},[1507],{"nctId":1508,"briefTitle":1509,"status":328,"phases":1510,"primaryCompletion":1511,"completion":1512,"start":1513,"enrollment":1514,"conditions":1515,"interventions":1516},"NCT04114149","Effective Postoperative Pain Relief After Laparoscopic Cholecystectomy With TENS",[70],"2023-01-23","2023-01-30","2019-03-19",166,[176],[1493],{"intervention":1518,"totalTrials":73,"cells":1519},"Infliximab",{"EARLY_PHASE1":1520,"PHASE1":1522,"PHASE2":1524,"PHASE3":1526,"PHASE4":1528,"NA":1530},{"trials":1521,"activeCount":77},[],{"trials":1523,"activeCount":77},[],{"trials":1525,"activeCount":77},[],{"trials":1527,"activeCount":77},[],{"trials":1529,"activeCount":77},[],{"trials":1531,"activeCount":77},[1532],{"nctId":1533,"briefTitle":1534,"status":328,"phases":1535,"primaryCompletion":1536,"completion":1536,"start":1537,"enrollment":1538,"conditions":1539,"interventions":1541},"NCT01850121","Remicade in the Treatment of Patients With Active Ankylosing Spondylitis",[],"2008-05","2003-01",19,[1540],"Ankylosing Spondylitis",[1518],{"intervention":1543,"totalTrials":73,"cells":1544},"alendronate",{"EARLY_PHASE1":1545,"PHASE1":1547,"PHASE2":1549,"PHASE3":1551,"PHASE4":1553,"NA":1555},{"trials":1546,"activeCount":77},[],{"trials":1548,"activeCount":77},[],{"trials":1550,"activeCount":77},[],{"trials":1552,"activeCount":77},[],{"trials":1554,"activeCount":77},[],{"trials":1556,"activeCount":77},[1557],{"nctId":1558,"briefTitle":1559,"status":328,"phases":1560,"primaryCompletion":1561,"completion":1561,"start":1409,"enrollment":16,"conditions":1562,"interventions":1564},"NCT01104987","Treatment With Alendronate in Patients With Ankylosing Spondylitis (AS)",[],"2016-07",[1540,1563],"Osteoporosis",[1543],{"intervention":1566,"totalTrials":73,"cells":1567},"Amitryptiline, gabapentin",{"EARLY_PHASE1":1568,"PHASE1":1570,"PHASE2":1572,"PHASE3":1574,"PHASE4":1576,"NA":1578},{"trials":1569,"activeCount":77},[],{"trials":1571,"activeCount":77},[],{"trials":1573,"activeCount":77},[],{"trials":1575,"activeCount":77},[],{"trials":1577,"activeCount":77},[],{"trials":1579,"activeCount":77},[1580],{"nctId":1581,"briefTitle":1582,"status":328,"phases":1583,"primaryCompletion":1584,"completion":433,"start":1585,"enrollment":1538,"conditions":1586,"interventions":1588},"NCT01020162","Treatment of Ilioinguinal Entrapment Syndrome - an Often Overlooked Cause of Chronic Pelvic Pain",[70],"2006-12","1995-09",[1587],"Chronic Pelvic Pain",[1566],{"intervention":1590,"totalTrials":73,"cells":1591},"TPN",{"EARLY_PHASE1":1592,"PHASE1":1594,"PHASE2":1596,"PHASE3":1598,"PHASE4":1600,"NA":1602},{"trials":1593,"activeCount":77},[],{"trials":1595,"activeCount":77},[],{"trials":1597,"activeCount":77},[],{"trials":1599,"activeCount":77},[],{"trials":1601,"activeCount":77},[],{"trials":1603,"activeCount":77},[1604],{"nctId":1605,"briefTitle":1606,"status":328,"phases":1607,"primaryCompletion":1608,"completion":1608,"start":1609,"enrollment":1385,"conditions":1610,"interventions":1612},"NCT03401944","Effects of Total Parenteral Nutrition on Skeletal Muscle Genomics.",[70],"2014-12-31","2005-01-01",[1611],"Wasting;Muscle(S)",[1590],{"intervention":1614,"totalTrials":73,"cells":1615},"Aspirin",{"EARLY_PHASE1":1616,"PHASE1":1618,"PHASE2":1620,"PHASE3":1622,"PHASE4":1624,"NA":1626},{"trials":1617,"activeCount":77},[],{"trials":1619,"activeCount":77},[],{"trials":1621,"activeCount":77},[],{"trials":1623,"activeCount":77},[],{"trials":1625,"activeCount":77},[],{"trials":1627,"activeCount":77},[1628],{"nctId":1629,"briefTitle":1630,"status":328,"phases":1631,"primaryCompletion":1283,"completion":1632,"start":1633,"enrollment":1634,"conditions":1635,"interventions":1637},"NCT02823743","RECAB-ASA; Treatment of Recurrent Abortion With Aspirin",[70],"2016-06","2008-03",400,[1636],"Abortion, Habitual",[1614]]